Page last updated: 2024-10-16

gamma-aminobutyric acid and Spinal Muscular Atrophies of Childhood

gamma-aminobutyric acid has been researched along with Spinal Muscular Atrophies of Childhood in 7 studies

gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.

Spinal Muscular Atrophies of Childhood: A group of recessive inherited diseases that feature progressive muscular atrophy and hypotonia. They are classified as type I (Werdnig-Hoffman disease), type II (intermediate form), and type III (Kugelberg-Welander disease). Type I is fatal in infancy, type II has a late infantile onset and is associated with survival into the second or third decade. Type III has its onset in childhood, and is slowly progressive. (J Med Genet 1996 Apr:33(4):281-3)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (57.14)29.6817
2010's2 (28.57)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Wadman, RI3
van der Pol, WL2
Bosboom, WM3
Asselman, FL1
van den Berg, LH4
Iannaccone, ST4
Vrancken, AF4
Lunn, MR1
Wang, CH1
Bosboom, W1
Wokke, JH3
Merlini, L1
Solari, A1
Vita, G1
Bertini, E1
Minetti, C1
Mongini, T1
Mazzoni, E1
Angelini, C1
Morandi, L1
Miller, RG1
Moore, DH1
Dronsky, V1
Bradley, W1
Barohn, R1
Bryan, W1
Prior, TW1
Gelinas, DF1
Iannaccone, S1
Kissel, J1
Leshner, R1
Mendell, J1
Mendoza, M1
Russman, B1
Samaha, F1
Smith, S1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Respiratory Muscle Training in Patients With Spinal Muscular Atrophy (SMA).[NCT05632666]30 participants (Actual)Interventional2021-02-02Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

5 reviews available for gamma-aminobutyric acid and Spinal Muscular Atrophies of Childhood

ArticleYear
Drug treatment for spinal muscular atrophy types II and III.
    The Cochrane database of systematic reviews, 2020, 01-06, Volume: 1

    Topics: Adolescent; Amines; Child; Child, Preschool; Creatine; Cyclohexanecarboxylic Acids; gamma-Aminobutyr

2020
Spinal muscular atrophy.
    Lancet (London, England), 2008, Jun-21, Volume: 371, Issue:9630

    Topics: Action Potentials; Amines; Cyclic AMP Response Element-Binding Protein; Cyclohexanecarboxylic Acids;

2008
Drug treatment for spinal muscular atrophy types II and III.
    The Cochrane database of systematic reviews, 2009, Jan-21, Issue:1

    Topics: Amines; Creatine; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Phenylbu

2009
Drug treatment for spinal muscular atrophy types II and III.
    The Cochrane database of systematic reviews, 2011, Dec-07, Issue:12

    Topics: Acetylcarnitine; Adolescent; Amines; Child; Child, Preschool; Creatine; Cyclohexanecarboxylic Acids;

2011
Drug treatment for spinal muscular atrophy types II and III.
    The Cochrane database of systematic reviews, 2012, Apr-18, Issue:4

    Topics: Acetylcarnitine; Adolescent; Amines; Child; Child, Preschool; Creatine; Cyclohexanecarboxylic Acids;

2012

Trials

2 trials available for gamma-aminobutyric acid and Spinal Muscular Atrophies of Childhood

ArticleYear
Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study.
    Journal of child neurology, 2003, Volume: 18, Issue:8

    Topics: Acetates; Adolescent; Adult; Amines; Arm; Child; Cyclohexanecarboxylic Acids; Female; Gabapentin; ga

2003
A placebo-controlled trial of gabapentin in spinal muscular atrophy.
    Journal of the neurological sciences, 2001, Oct-15, Volume: 191, Issue:1-2

    Topics: Acetates; Adult; Amines; Arm; Cyclohexanecarboxylic Acids; Double-Blind Method; Excitatory Amino Aci

2001